News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

Local biotechnology company, Grace Bio-Labs, makes clinical grade hand sanitizer for area hospitals available to the public

Not all hand sanitizers are made the same; Efficacy is compromised in many cheaper brands

Local Bend based Biotechnology company, Grace Bio Labs, has been producing pharmaceutical grade hand sanitizer exclusively for St. Charles Hospitals since the beginning of the pandemic. Grace Bio Labs formula was developed as a clinical grade I product and is made from 70% isopropanol, meeting WHO recommended and CDC guidelines for effectiveness in killing most bacteria and many viruses, like Covid-19.

By pivoting their production during this […]

July 29, 2020 |

Oregon mentors needed in early August: National ICorps Bio-entrepreneur program for underrepresented early career researchers

WHO: Mentor early-career life science researchers from groups underrepresented in biotechnology research organizations. Participants include research-active assistant professors, postdoctoral fellows, graduate students and advanced undergraduates from universities and colleges nationwide.

WHY: • Promote diversity within Biotechnology in your region by engaging with underrepresented workshop participants
• Connect with participants in your region and provide ongoing resources
• Work with teams as they solve problems through entrepreneurial concepts
• Assist teams in developing a professional network and provide feedback as they execute customer discovery through BIO’s […]

July 27, 2020 |

Veana announces clinical collaboration with University of Washington for novel oral oncology candidate, Alpha-TEA in advanced HER2+ breast cancer

Phase I Study to Evaluate alpha-TEA in Combination With Trastuzumab (HerceptinTM) in Patients with Advanced HER2 Positive Breast Cancer
Portland, OR July 24, 2020

Veana Therapeutics Inc. is pleased to announce that it has entered into a clinical research collaboration with the University of Washington to conduct a Phase I clinical trial of its lead agent, alpha-TEA (aka a-TEA lysine) in combination with trastuzumab (HerceptinTM) in HER2+ breast cancer patients. a-TEA lysine salt is a novel, first-in-class small molecule that destabilizes mitochondria […]

Alpha Cancer technologies to license AbSci’s SoluPro strain for the expression of alpha-fetoprotein

VANCOUVER, Wash., July 21, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers.  This license is […]

July 24, 2020 |

Voice of Academia: Part 2 – Commercialization is happening at the launch of UO’s new science campus

Oregon Bio has launched an occasional series called Voice of Academia and today, we’re bringing Part 2 (see Part 1 here) of our talk with University of Oregon professor and faculty member at the Phil and Penny Knight Campus for Accelerating Scientific Impact, Keat Ghee Ong, Ph.D. Dr. Ghee launched the Ong Lab as well as Penderia Technologies, Inc. and here, he explains his work starting up:

Q: How has Knight Campus programming supported your efforts […]

July 13, 2020 |

Current growth in bioscience and medtech sectors drives upward demand for industry-vetted BioPro education

(Portland, Ore.) – With hiring and growth happening at dozens of scientific, manufacturing and biotech companies in the Pacific Northwest, the Oregon Bioscience Association has retooled its myriad educational workforce training, classes and workshops to now be offered online live with industry-expert instructors, through its well-known BioPro program.

The recently released Biotechnology Innovation Organization/TEConomy 2020 report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State and Local Communities, analyzes the bioscience industry’s economic footprint across the nation and in Oregon. […]

July 7, 2020 |

An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences

June 29, 2020

In the weeks since we learned of remdesivir’s potential against COVID-19, one topic has attracted more speculation than any other: what price we might set for the medicine. This degree of speculation is understandable. Remdesivir, our investigational treatment, is the first antiviral to have demonstrated patient improvement in clinical trials for COVID-19 and there is no playbook for how to price a new medicine in a pandemic. We are aware of the significant responsibility that comes with pricing […]

June 29, 2020 |

Voice of Academia: Part 1 – Driving toward student career paths’ diversity and the launch of UO’s new science campus

Oregon Bio has launched an occasional series called Voice of Academia to spotlight academic partnerships and commercialization opportunities as well as advances in research in the Pacific Northwest’s bioscience and medical technology ecosystem. In this profile, we explore the talented bench at UO’s new science campus and how a company is spinning off to meet global demand for implantable and wireless sensors, electronic devices and magneto-elastic materials.

At the University of Oregon, we recently interviewed a professor and faculty member at the Phil […]

BIO Announces 2020 Start-up Stadium Winners: Sparrow Pharmaceuticals among the top five

Washington, DC – (June 26, 2020) – The Biotechnology Innovation Organization (BIO) today announced winners of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 30 finalists were evaluated by expert judges with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors. A total of five winners were chosen across three groups. Competitors from around the globe were judged on the strength of their commercially viable […]